Stocks and Finance

Exelixis

Exelixis 2/15/2012

17:45 : Stock offering nets Exelixis $65 million - Exelixis Inc. will net $65 million by selling 12.65 million shares of common stock, the South San Francisco biotech cancer drug developer said Wednesday. The total includes 1.65 million shares that the underwriters opted to buy. Exelixis ...
Source : bizjournals-com

Exelixis 12/21/2011

10:45 : Exelixis ([[EXEL]] +3.6%) says it's licensed its PI3K-delta research and ... - Exelixis (EXEL +3.6%) says it's licensed its PI3K-delta research and development program to Merck (MRK +0.2%) for $12M plus an additional $239M in combined milestone and royalty payments. The sale will allow the company to ...
Source : seekingalpha-com

Exelixis 11/1/2011

11:13 : Exelixis plunges on drug study woes - BOSTON (MarketWatch) -- Shares of Exelixis Inc. plunged almost 40% to $4.70 on Tuesday, a day after the biotech group said that it plans to go ahead with a key Phase III clinical trial for its drug candidate cabozantinib despite not having ...
Source : marketwatch-com

Exelixis 10/31/2011

17:35 : Exelixis (EXEL) resumes trading after a long halt, now down 33.4% AH, ... - Exelixis (EXEL) resumes trading after a long halt, now down 33.4% AH, after announcing it's initiating its first phase 3 trial of cabozantinib for patients with a particular type of prostate cancer. Without an agreement with the FDA, the ...
Source : seekingalpha-com
17:32 : Exelixis shares fall without FDA study commentary - SAN FRANCISCO (MarketWatch) -- Exelixis Inc. shares fell late Monday after the biotech drug developer said it will pursue a late-stage clinical trial for a prostate cancer treatment without supporting comments from the Food and Drug Administration. ...
Source : marketwatch-com

Exelixis 10/24/2011

11:07 : Exelixis rallies 21% on drug study - BOSTON (MarketWatch) -- Shares of Exelixis Inc. shot up 21% to $7.25 on Monday after the biotech firm unveiled positive preliminary results from a Phase III study for its drug candidate cabozantinib in the treatment of a type of thyroid ...
Source : marketwatch-com
08:34 : Shares of Exelixis (EXEL) gain 20% premarket after the firm announces ... - Shares of Exelixis (EXEL) gain 20% premarket after the firm announces positive top-line results from its Phase 3 clinical trail of cabozantinib in patients with medullary thyroid cancer. The company aims to build a cabozantinib franchise ...
Source : seekingalpha-com

Exelixis 7/27/2011

17:58 : Growing Threshold, Nodality sublease Exelixis space - Exelixis Inc. is unloading more than 53,000 square feet in South San Francisco to two up-and-coming companies. Exelixis (NASDAQ: EXEL), which once had a workforce more than 600, said it will sublease 28,180 square feet at ...
Source : bizjournals-com

Exelixis 6/7/2011

10:34 : Health-care Stocks: ASCO studies move Exelixis, Sunesis, Oxigene - Shares of Exelixis, Sunesis, and Oxigene are moving on presentations made on their respective cancer drugs at the annual meeting of the American Society of Clinical Oncology, or ASCO.
Source : marketwatch-com

Exelixis 6/6/2011

14:58 : Biotech Stocks: Exelixis, Sunesis lead drug stocks lower - Shares of Exelixis plunge after the company reveals that six patients in a clinical trial for its cancer agent cabozantinib died of drug-related complications.
Source : marketwatch-com
14:32 : Exelixis sinks 18% on drug-safety concerns - BOSTON (MarketWatch) -- Shares of Exelixis Inc. sank 19% to $8.85 in afternoon trading Monday after the company released data from a Phase II clinical trial for its cancer-fighting agent cabozantinib that showed six drug-related deaths, ...
Source : marketwatch-com
actualidad Exelixis -


Biotechnology

Pharmaceuticals

Medical Supplies

Medical Equipment

Health Care Providers

Copyright © 2009 Finaperf.com - Exchange rate - Investir - Stock Exchange - Börse - Finanças - Bolsa - Tous droits réservés
Site édité par Yanga.net - Contacts